A phase II trial of nilotinib in the treatment of patients with KIT mutated advanced acral and mucosal melanoma (NICAM)

Authors :: Sarah Sarker
Claire Snowdon
James Larkin
Paul Nathan
G Coombes
M. G. James
Judith M Bliss
J. Griffiths
Paul Lorigan
Samra Turajlic
D. Gonzalez de Castro
Gordon Stamp
N. Martin
Kim Edmonds
M. E. Gore
Richard Marais
Roger A'Hern
Source :: Journal of Clinical Oncology. 29:TPS229-TPS229
Publication Year :: 2011
Publisher :: American Society of Clinical Oncology (ASCO), 2011.
Abstract: TPS229 Background: Recent studies have indicated that KIT mutations occur in approximately 20% of acral and mucosal melanomas (Curtin, al. 2006; Beadling, et al. 2008). Several case reports have sh...

Subjects :: Cancer Research
Pathology
medicine.medical_specialty
integumentary system
Oncology
Nilotinib
business.industry
Cancer research
Mucosal melanoma
medicine
medicine.disease
business
medicine.drug

Full Text Access

Tools